Natco Pharma seeks compulsory licensing for COVID medicines

[{"selector":"#anim-50dba692-abb0-45e5-b706-76d648b7a563","keyframes":{"transform":["translate3d(0px, 100%, 0)","translate3d(0px, 0px, 0)"]},"delay":350,"direction":"normal","duration":600,"easing":"cubic-bezier(0.445, 0.05, 0.55, 0.95)","fill":"both"}] Natco Pharma seeks compulsory licensing for COVID medicines

[{"selector":"#anim-31864c77-942f-4e2f-a483-6568f794e0a0","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] [{"selector":"#anim-524e27f4-e03a-4dbe-83e0-9b896201a43a","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":100,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] [{"selector":"#anim-7baa5572-08ab-4777-9434-2874e3ad3b0d","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":200,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] NEWS Natco Pharma seeks compulsory licensing for COVID medicines By Pallavi Paul While India is facing the second wave of coronavirus pandemic, Indian pharmaceutical company Natco Pharma filed an application before the Patent Controller Office, Mumbai seeking compulsory licensing on Covid drug ‘Baricitinib’ which is used in combination with Remdesivir for the treatment of Covid-19. Natco Pharma had initially been approved emergency use of ‘Baricitinib’ medicine by the Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid positive patients. But due to its expensive price, many Indians are not in the state to afford the medicine as the average cost for the medicine starts with Rs 3000 per tablet.

[{"selector":"#anim-d541a5e6-da15-4bfe-bfbb-76fc24c7a2f1","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] [{"selector":"#anim-716b391f-980a-43f7-a7d7-ba4536bba48b","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":100,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] [{"selector":"#anim-14a86574-981f-4f31-afe7-db0b8d047e98","keyframes":{"transform":["translate3d(-100%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":200,"direction":"normal","duration":1000,"easing":"cubic-bezier(0.645, 0.045, 0.355, 1)","fill":"both"}] NEWS By Pallavi Paul For the 14-day treatment of Covid positive patients, it is beyond imagination for a normal person to afford the medicine at any cost. Natco offers to sell the medicine at a minimal cost of Rs 10 to Rs 30 per tablet depending upon the mg variants. Further, it also offered to pay 7% royalty on net profits to the patent holder of the medicine. The only intention of the company is to provide affordable and accessible medicine to Indians at the time of crisis. It is pertinent to mention that, India’s first compulsory license had been granted to Natco Pharma for Bayer Corporation’s cancer drug 'Nexavar.' PAGE 2/2